Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era ...

WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be ...

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.